COEPTIS, Inc. announced on February 6, 2025, the successful closure of an additional $5.7 million in its final Series A Preferred Offering. This brings the total financing round to $10 million, reinforcing the company's commitment to technological innovation and AI integration. The significant achievement highlights investor confidence in Coeptis' innovative solutions and strategic pivot.
The financing was led by CJC Investment Trust, an entity controlled by board member Christopher Calise, through an increase in their initial investment. Under the terms, the Series A Preferred is convertible into common stock at $8.00 per share, subject to limitations. Investors also received an aggregate 15% equity interest in the newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.
Brian Cogley, CFO of COEPTIS, stated that this funding is pivotal as the company expands its operational capabilities and enhances shareholder value through its new Technology Division. The integration of AI-driven tools, particularly from the recent acquisition of the NexGenAI Affiliates Network platform, is vital in revolutionizing the company's approach to marketing and operational efficiencies.
The proceeds from this financing will be utilized to strengthen the company's balance sheet, repay outstanding obligations, and support general corporate purposes. The additional capital will also accelerate Coeptis' ongoing integration of advanced AI solutions and automation capabilities. This enhances both research processes and the overall operational framework of the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.